Possible impact of dropout in a study of high-dose olanzapine and prolactin levels.
Andrade
Chittaranjan
C
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood / Q000139:chemically induced*; D000077152:Olanzapine; D010352:Patient Dropouts; D018579:Patient Selection; D011388:Prolactin / Q000097:blood*; D012107:Research Design / Q000592:standards
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D011388:Prolactin; D000077152:Olanzapine